INDGN · Healthcare · Health Information Services
Composite scorecard: 61/100 — Quality 68 · Valuation 44 · Growth 94 · Momentum 17
| Share price | ₹509.10 |
| Market cap | ₹11,927 Cr |
| P/E ratio | 27.3 |
| P/B ratio | 4.2 |
| ROE | 12.8% |
| ROCE | 20.3% |
| Dividend yield | 0.40% |
| Book value | ₹119.56 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹3,510 Cr | ₹401 Cr | 18.0% |
| 2025 | ₹2,839 Cr | ₹407 Cr | 19.0% |
| 2024 | ₹2,590 Cr | ₹337 Cr | 20.0% |
| 2023 | ₹2,306 Cr | ₹266 Cr | 17.0% |
| 2022 | ₹1,665 Cr | ₹163 Cr | 17.0% |
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, tech